News headlines about Glaukos Corporation (NYSE:GKOS) have been trending somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Glaukos Corporation earned a news impact score of 0.20 on Accern’s scale. Accern also gave news stories about the medical instruments supplier an impact score of 46.2499495662239 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern’s rankings:
- Glaukos Corporation (GKOS) Analysts Remain Upbeat Despite -27.97% Loss – AllStockNews (allstocknews.com)
- Is Glaukos Corporation (GKOS) Dependable Investment For Shareholders? – AllStockNews (allstocknews.com)
- Glaukos Corporation (NYSE:GKOS) Closed -5.1% Below Its 50 Day Average – Modern Readers (modernreaders.com)
- Insider Selling: Glaukos Corp (GKOS) Director Sells 325,000 Shares of Stock (americanbankingnews.com)
- BidaskClub Upgrades Glaukos Corporation (GKOS) to Hold (americanbankingnews.com)
A number of equities analysts have issued reports on GKOS shares. Stephens raised Glaukos Corporation from an “equal weight” rating to an “overweight” rating in a report on Monday, May 8th. Zacks Investment Research cut Glaukos Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, May 2nd. BidaskClub raised Glaukos Corporation from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. TheStreet cut Glaukos Corporation from a “c” rating to a “d+” rating in a research note on Wednesday, May 3rd. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $54.00 price target on shares of Glaukos Corporation in a research note on Thursday, May 4th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Glaukos Corporation has an average rating of “Buy” and an average target price of $52.33.
Shares of Glaukos Corporation (NYSE:GKOS) opened at 37.45 on Friday. The stock has a 50 day moving average price of $39.65 and a 200 day moving average price of $43.18. Glaukos Corporation has a 52 week low of $28.26 and a 52 week high of $52.49. The firm’s market cap is $1.29 billion.
In other news, Director Orbimed Advisors Llc sold 325,000 shares of the business’s stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $37.93, for a total value of $12,327,250.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 16.40% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Glaukos Corporation (NYSE:GKOS) Share Price” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.com-unik.info/2017/08/19/glaukos-corporation-nysegkos-earning-somewhat-favorable-media-coverage-report-finds-updated-updated.html.
About Glaukos Corporation
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
What are top analysts saying about Glaukos Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Glaukos Corporation and related companies.